文献类型：期刊文献

英文题名：Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis

作者：Zhang, Chengren[1,2,3];Liu, Lili[4];Lv, Yaochun[2,3,5];Li, Jingjing[1,2,3];Cao, Cong[1,2,3];Lu, Jiyong[2,3,4];Wang, Shuai[2,3,4];Du, Binbin[2,3];Yang, Xiongfei[2,3,5]

第一作者：Zhang, Chengren

通信作者：Lv, YC[1];Yang, XF[1]

机构：[1]Ningxia Med Univ, Gen Hosp, Yinchuan, Peoples R China;[2]Gansu Prov Peoples Hosp, Dept Anorectal Surg, Lanzhou, Peoples R China;[3]Gansu Prov Peoples Hosp, Anorectal Dis Res Ctr, Lanzhou, Peoples R China;[4]Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou, Peoples R China;[5]Gansu Prov Peoples Hosp, Dept Anorectal Surg, Lanzhou 730000, Peoples R China

第一机构：Ningxia Med Univ, Gen Hosp, Yinchuan, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Peoples Hosp, Dept Anorectal Surg, Lanzhou 730000, Peoples R China.

年份：2022

卷号：22

期号：12

起止页码：1333

外文期刊名：EXPERT REVIEW OF ANTICANCER THERAPY

收录：;Scopus(收录号：2-s2.0-85142619574);WOS:【SCI-EXPANDED(收录号:WOS:000889221200001)】；

基金：This manuscript was funded by the Scientific Research Fund of Gansu Provincial People's Hospital (20GSSY3-1, 21GSSYC-20) and Foundation of Lanzhou Science and Technology Bureau (2022-ZD-47).

语种：英文

外文关键词：Metastatic colorectal cancer; chemotherapy; panitumumab; cetuximab; bevacizumab; meta analysis

摘要：ObjectiveIt remains controversial which targeted monoclonal antibodies combined with chemotherapy can provide better efficacy in wild-type KRAS/RAS metastatic colorectal cancer (mCRC) patients. Therefore, we used this meta-analysis to assess the latest evidence of clinical outcomes.Materials and methodsWe systematically searched PubMed, Web of Science, Cochrane Library and Embase databases for eligible studies published from database inception to May 2022. RevMan 5.4 was used to conduct the meta-analysis.Results11 RCTs involving a total of 3575 patients were included. Meta-analysis showed that EGFR inhibitors significantly prolonged the overall survival (OS) [HR = 0.83, 95%CI (0.73, 0.94), P = 0.003] and overall response rate (ORR) [RR = 1.11, 95%CI (1.05, 1.18), P = 0.0003] compared to VEGF inhibitors in wild-type KRAS/RAS mCRC patients, but no significant difference in progression-free survival (PFS) [HR = 0.96, 95%CI (0.87, 1.07), P = 0.50]. In subgroup analysis, the survival benefit of EGFR inhibitors was limited to first-line treatment.ConclusionOur study showed that EGFR inhibitors were superior to VEGF inhibitors in wild-type KRAS/RAS mCRC patients, especially in patients with first-line treatment. However, subsequent large sample, multi-center RCTs are needed to further verify our conclusions.